Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A mantle cell lymphoma that affects the stomach. It may arise as a solitary mass or it may be a component of multifocal lymphomatous polyposis of the gastrointestinal tract. It usually has an aggressive clinical course.
Biomarker and diagnostic research for gastric mantle cell lymphoma has been reported in the published literature.
No clinical trials have been registered for gastric mantle cell lymphoma.
14 publications have been identified in PubMed for gastric mantle cell lymphoma. Research spans Case Report / Case Series (36%), Epidemiology / Natural History (21%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 36% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 11:35 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
3 |
21% |
Testing and diagnosis research | 2 | 14% |
Research summaries | 2 | 14% |
Laboratory research | 1 | 7% |
New treatment approaches | 1 | 7% |
A S (2026). [PMID: 42199578](https://pubmed.ncbi.nlm.nih.gov/42199578/). *Cureus*. [Review / Meta-Analysis]
GBD 2023 Causes of Death Collaborators (2025). [PMID: 41092928](https://pubmed.ncbi.nlm.nih.gov/41092928/). *Lancet*. [Epidemiology / Natural History]
Filizoglu N (2025). [PMID: 39480266](https://pubmed.ncbi.nlm.nih.gov/39480266/). *Clin Nucl Med*. [Case Report / Case Series]
Ziani I (2025). [PMID: 40318485](https://pubmed.ncbi.nlm.nih.gov/40318485/). *Int J Surg Case Rep*. [Case Report / Case Series]
Zhang Q (2025). [PMID: 39087661](https://pubmed.ncbi.nlm.nih.gov/39087661/). *Rev Esp Enferm Dig*. [Case Report / Case Series]
Filip PV (2025). [PMID: 40117560](https://pubmed.ncbi.nlm.nih.gov/40117560/). *J Gastrointestin Liver Dis*. [Epidemiology / Natural History]
Barioni CTS (2025). [PMID: 40550549](https://pubmed.ncbi.nlm.nih.gov/40550549/). *Korean J Helicobacter Up Gastrointest Res*. [Case Report / Case Series]
Rai S (2025). [PMID: 40916449](https://pubmed.ncbi.nlm.nih.gov/40916449/). *Future Oncol*. [Epidemiology / Natural History]
Wang YK (2025). [PMID: 40455334](https://pubmed.ncbi.nlm.nih.gov/40455334/). *J Mol Histol*. [Basic Science / Preclinical]
Kumar KA (2025). [PMID: 40310320](https://pubmed.ncbi.nlm.nih.gov/40310320/). *Int J Radiat Oncol Biol Phys*. [Review / Meta-Analysis]
AI-curated news mentioning gastric mantle cell lymphoma
Updated Sep 10, 2026
NICE has endorsed the use of ibrutinib in combination therapy for untreated mantle cell lymphoma, providing a new alternative to transplant-based first-line treatments. This decision marks a significant shift in treatment options for patients with this aggressive form of lymphoma.
A recent study highlights a rare paraneoplastic syndrome where mantle cell lymphoma manifests as bullous pemphigoid. This discovery may enhance understanding of the relationship between hematological malignancies and autoimmune skin disorders.
NICE has approved new combination regimens involving Acalabrutinib for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). This decision enhances treatment options for patients with these blood cancers.
BeOne's Beqalzi becomes the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma, marking a significant advancement in treatment options for this patient population. This approval opens the door for new therapeutic strategies in managing this challenging disease.
FDA announces the initiation of proof-of-concept real-time clinical trials (RTCTs) by AstraZeneca and Amgen, aiming to accelerate drug development. AstraZeneca's Phase 2 trial, TRAVERSE, targets treatment-naïve mantle cell lymphoma and involves collaboration with leading cancer centers.